For Research Use Only. Not for use in diagnostic procedures.
Detecting circulating tumor cells (CTCs) remains a significant analytical challenge due to their extreme rarity. Only about 1–10 CTCs are typically present per mL of whole blood, and current technologies often must identify a single CTC among nearly 10 million nucleated blood cells. This rarity drives the need for highly sensitive platforms capable of resolving these exceptionally scarce events.
The AXON Dx imaging systems were originally developed to address the technical challenges of circulating tumor cell (CTC) detection and have evolved into adaptable rare-cell research platforms.
Key capabilities include:
- Multi-channel fluorescence imaging
- Automated whole-slide scanning
- High-resolution digital image capture
- AI-assisted cellular identification
- Structured data archiving
AXON Dx’s nCYTE™
AXON Dx technology supports research in:
- Circulating tumor cell (CTC) studies
- Rare cell analysis such as circulating stromal cells and circulating endothelial cells
- Translational oncology research
- Assay development and validation
AXON Dx™ Products
AXON Dx™ Products
AXON Dx’s nCyte™ technology
AXON Dx’s nCyte™ technology scans un-enriched blood samples in minutes, finds all classes of rare cells such as CTCs shed by solid tumors, and offers morphological and proteomic and genomic characterization of positive cells.
AXON Dx products are designed to support research and translational investigations in: Circulating tumor cell studies, Rare-cell enumeration, Oncology biomarker research, Assay feasibility and validation studies, Academic and industry collaborations
AXON Cell images
Transforming Diagnosis of Benign Pelvic Diseases
Collaboration
AXON Dx engages in research collaborations and strategic technology partnerships within the rare-cell detection ecosystem.